Sichuan Huiyu Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 6.64%

Sichuan Huiyu Pharmaceutical Co Ltd (688553) has an Asset Resilience Ratio of 6.64% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sichuan Huiyu Pharmaceutical Co Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥323.67 Million
≈ $47.36 Million USD Cash + Short-term Investments

Total Assets

CN¥4.88 Billion
≈ $713.55 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Sichuan Huiyu Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Sichuan Huiyu Pharmaceutical Co Ltd's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Sichuan Huiyu Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Sichuan Huiyu Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥323.67 Million 6.64%
Total Liquid Assets CN¥323.67 Million 6.64%

Asset Resilience Insights

  • Limited Liquidity: Sichuan Huiyu Pharmaceutical Co Ltd maintains only 6.64% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Sichuan Huiyu Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Sichuan Huiyu Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
Drug Manufacturers - Specialty & Generic 47.16%
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
Drug Manufacturers - Specialty & Generic 6.62%
Piramal Pharma Limited
NSE:PPLPHARMA
Drug Manufacturers - Specialty & Generic 0.73%
Harbin Gloria Pharmaceuticals
SHE:002437
Drug Manufacturers - Specialty & Generic 9.04%
Renhe Pharmacy Co Ltd
SHE:000650
Drug Manufacturers - Specialty & Generic 37.54%

Annual Asset Resilience Ratio for Sichuan Huiyu Pharmaceutical Co Ltd (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Sichuan Huiyu Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 13.33% CN¥688.59 Million
≈ $100.76 Million
CN¥5.17 Billion
≈ $755.89 Million
-3.51pp
2023-12-31 16.84% CN¥789.05 Million
≈ $115.46 Million
CN¥4.69 Billion
≈ $685.66 Million
-15.33pp
2022-12-31 32.17% CN¥1.38 Billion
≈ $201.34 Million
CN¥4.28 Billion
≈ $625.79 Million
-8.08pp
2021-12-31 40.25% CN¥1.66 Billion
≈ $243.23 Million
CN¥4.13 Billion
≈ $604.28 Million
+21.45pp
2020-12-31 18.80% CN¥228.00 Million
≈ $33.36 Million
CN¥1.21 Billion
≈ $177.46 Million
-1.90pp
2019-12-31 20.70% CN¥178.00 Million
≈ $26.05 Million
CN¥859.98 Million
≈ $125.84 Million
--
pp = percentage points

About Sichuan Huiyu Pharmaceutical Co Ltd

SHG:688553 China Drug Manufacturers - Specialty & Generic
Market Cap
$687.42 Million
CN¥4.70 Billion CNY
Market Cap Rank
#10750 Global
#2947 in China
Share Price
CN¥11.09
Change (1 day)
-0.09%
52-Week Range
CN¥9.86 - CN¥25.10
All Time High
CN¥38.07
About

Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more